Brief: Oncosec To Present Positive Interim Data From Keynote-695 Trial In Anti-Pd-1 Checkpoint Refractory Metastatic Melanoma At Sitc 2020
03/11/2020 14:04
Nov 3 (Reuters) - OncoSec Medical Inc ONCS.O :
* ONCOSEC TO PRESENT POSITIVE INTERIM DATA FROM KEYNOTE-695
TRIAL
IN ANTI-PD-1 CHECKPOINT REFRACTORY METASTATIC MELANOMA AT SITC
2020
Source text for Eikon: ID:nPn8DGgr4a
Further company coverage: ONCS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on OncoSec Medical Incorporated
See all newsBrief: OncoSec Medical Inc On June 15 Received Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard From Nasdaq
U.S. STOCKS ON THE MOVE-Domino's, Aldeyra, MicroVision
Brief: OncoSec Medical Files Voluntary Petition For Relief Under Provisions Of Chapter 7 Of Title 11 Of United States Code
Brief: OncoSec Medical Terminates George Chi For Cause As Employee, CFO
Brief: Oncosec Medical Receives Non Compliance Notice From Nasdaq